Biopharmaceutical CMO and CRO Market Size & Growth Forecast 2027–2036, By Segments (Source, Service Type, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Biopharmaceutical CMO and CRO Market size was over USD 42.74 billion in 2026 and is likely to grow at a 5.32% CAGR between 2027 and 2036, surpassing USD 71.77 billion by 2036. The industry revenue for 2027 is estimated at USD 44.65 billion.
Get more details on this report
Request Free Sample ReportBiopharmaceutical CMO and CRO Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 35.10% share due to strong biopharma base, mature outsourcing networks, and advanced infrastructure supporting clinical development and manufacturing services.
- Asia Pacific is growing at 6.44% CAGR driven by increasing outsourcing demand, expanding service capabilities, and cost-efficient scalable clinical and manufacturing operations.
Segment Momentum
- Contract Manufacturing accounted for 60.9% of the market in 2026 because biopharmaceutical companies depend on outsourced manufacturing capacity, specialized facilities, and scalable production for commercial biologics.
- Non-mammalian platforms are expanding fastest as developers seek faster process development, lower production complexity, and improved cost efficiency for suitable biologics and research-stage programs.
Market Expansion Drivers
- Increasing outsourcing of biologics manufacturing driving contract development and production demand.
- Adoption of single-use bioprocessing systems improving scalability and reducing production turnaround time.
- Rising complexity of biologics pipelines increasing reliance on specialized CDMO service providers.
Leading Market Participants
- Leading companies in the biopharmaceutical CMO and CRO market include Lonza Group AG (Switzerland), Thermo Fisher Scientific Inc. (United States), WuXi Biologics (China), Charles River Laboratories International, Inc. (United States), ICON plc (Ireland), Parexel International Corporation (United States), FUJIFILM Diosynth Biotechnologies U.S.A., Inc. (United States), Boehringer Ingelheim International GmbH (Germany), Rentschler Biopharma SE (Germany), Samsung Biologics Co., Ltd. (South Korea).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 42.74 billion
- 2027 Estimated Market Size: USD 44.65 billion.
- Projected Market Size: USD 71.77 billion by 2036
- Growth Forecast: 5.32% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Mammalian (Source) | Contract Manufacturing (Service Type) | Biologics (Product)
- Emerging Opportunity Segment: Non-mammalian (Source) | Contract Research (Service Type) | Biosimilars (Product)
Market Growth Drivers and Industry Trends
Increasing outsourcing of biologics manufacturing driving contract development and production demand
The biopharmaceutical CMO and CRO market is expanding as drug developers increasingly outsource manufacturing activities to specialized external providers to access technical capabilities, production infrastructure, and flexible capacity. Biologics manufacturing involves complex processes, stringent quality requirements, and specialized facilities, making internal development and production resource-intensive for many pharmaceutical and biotechnology companies. Outsourcing enables developers to concentrate on research, clinical development, and commercialization while external partners manage process development, scale-up, production, and associated quality activities. The growing use of external manufacturing networks also allows sponsors to adjust production resources according to pipeline requirements without making equivalent investments in dedicated facilities and equipment.
Adoption of single-use bioprocessing systems improving scalability and reducing production turnaround time
Adoption of disposable and single-use technologies is reshaping production operations within the biopharmaceutical CMO and CRO market by enabling more flexible and efficient bioprocessing workflows. Single-use systems can reduce the need for extensive equipment cleaning and sterilization between production cycles, supporting faster changeovers and lowering operational complexity. These systems are particularly valuable for multiproduct facilities and smaller production batches, where manufacturers need to accommodate varied client requirements while maintaining stringent process controls. Greater use of single-use bags, assemblies, bioreactors, and filtration systems can also simplify facility configuration and support scalable manufacturing approaches for biologics with different production requirements.
Rising complexity of biologics pipelines increasing reliance on specialized CDMO service providers
Increasingly sophisticated biologics pipelines are creating stronger demand for specialized expertise across development, process optimization, analytical testing, and commercial-scale manufacturing, supporting the biopharmaceutical CMO and CRO market. Modern pipelines can involve complex molecules, specialized formulations, advanced production processes, and demanding regulatory requirements that require capabilities beyond conventional manufacturing infrastructure. External service providers with dedicated technical teams and specialized facilities can help developers address these requirements while reducing the need to build every capability internally. As pipeline complexity grows, sponsors are increasingly seeking integrated partners that can support multiple stages of development and manufacturing while maintaining consistent quality and process control.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing outsourcing of biologics manufacturing driving contract development and production demand | 2.50% | High | North America, Europe, Asia Pacific | High | Near Term |
| Adoption of single-use bioprocessing systems improving scalability and reducing production turnaround time | 1.90% | High | North America, Europe | High | Mid Term |
| Rising complexity of biologics pipelines increasing reliance on specialized CDMO service providers | 1.60% | High | North America, Europe | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the biopharmaceutical CMO and CRO market at 35.10% in 2026, supported by a mature biopharmaceutical ecosystem, advanced research infrastructure, and strong demand for outsourced development and manufacturing services. Biopharmaceutical companies increasingly rely on specialized external partners to access technical capabilities, accelerate development activities, and manage complex production requirements. The region's established clinical research environment, sophisticated manufacturing infrastructure, and concentration of biotechnology activity continue to support outsourcing across development and commercialization stages.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is experiencing the fastest growth in the biopharmaceutical CMO and CRO market, supported by expanding biotechnology capabilities, improving research infrastructure, and increasing investment in pharmaceutical development and manufacturing. The region offers growing capacity for clinical research, drug development, analytical services, and biopharmaceutical production, encouraging greater use of specialized outsourcing partners. Expansion of healthcare systems and increasing focus on developing local biopharmaceutical capabilities are further strengthening regional demand.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision biologics manufacturingIn Germany, the biopharmaceutical CMO and CRO market is shaped by precision-driven biologics manufacturing and stringent compliance expectations across clinical research operations. Germany focuses on high-quality process development and specialized contract manufacturing for complex molecules, with strong integration between research institutes and industrial-scale production partners.
France 🇫🇷
Specialized clinical outsourcingIn France, the biopharmaceutical CMO and CRO market is supported by a strong clinical research infrastructure and specialization in early-stage clinical outsourcing services. France prioritizes collaboration between academic hospitals and contract organizations, enabling efficient execution of complex clinical studies and biologics development programs.
Italy 🇮🇹
Niche biologics specializationIn Italy, the biopharmaceutical CMO and CRO market is characterized by niche specialization in biologics and strong involvement of mid-sized contract manufacturers serving European pharmaceutical demand. Italy focuses on cost-efficient clinical trial operations and targeted manufacturing capabilities for specific therapeutic areas.
Japan 🇯🇵
Automation-led clinical trialsIn Japan, the biopharmaceutical CMO and CRO market reflects strong adoption of automation and data-driven clinical trial management to address efficiency and regulatory complexity. Japan emphasizes high-precision manufacturing and streamlined CRO services, with increasing collaboration between domestic pharma firms and global contract service networks.
South Korea 🇰🇷
Biotech scale-up partnerIn South Korea, the biopharmaceutical CMO and CRO market is increasingly positioned around biotech scale-up and advanced clinical outsourcing supported by government-backed innovation ecosystems. South Korea focuses on rapid clinical development cycles and biologics production capabilities aligned with global pharmaceutical partnerships.
United States 🇺🇸
Integrated outsourcing hubIn the biopharmaceutical CMO and CRO market, the United States concentrates strong demand from large pharma outsourcing and biotech innovation networks. The U.S. emphasizes end-to-end development partnerships, with companies prioritizing scalable clinical trial support and advanced biologics manufacturing capacity across established contract service providers.
Segment Leadership and Growth Trends
Biopharmaceutical CMO and CRO Market Share (%), by Source, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportSource Segment Analysis: Mammalian (Largest Segment) vs Non-mammalian (Fastest-Growing Segment)
Mammalian systems dominated the biopharmaceutical CMO and CRO market in 2026, accounting for 59.77% share, due to their established role in producing complex biologics that require sophisticated expression systems and manufacturing capabilities. Mammalian platforms are particularly important for products where appropriate protein folding, post-translational modifications, and biological activity are critical. Their established regulatory familiarity, extensive industry experience, and suitability for complex biologic production continue to support strong outsourcing demand.
Non-mammalian systems are expanding at the fastest pace as biopharmaceutical developers increasingly explore alternative expression platforms that can provide production flexibility, shorter development timelines, and potentially more efficient manufacturing. Microbial and other non-mammalian systems are particularly relevant for selected biologics and recombinant products where mammalian expression is not essential. Growing interest in cost optimization, process innovation, and diversified biologics manufacturing is encouraging greater use of these platforms.
Service Type Segment Analysis: Contract Manufacturing (Largest Segment) vs Contract Research (Fastest-Growing Segment)
Contract manufacturing represented the largest share of the biopharmaceutical CMO and CRO market in 2026 at 60.9%, reflecting the substantial need for external production capabilities across development and commercialization stages. Outsourcing manufacturing enables biopharmaceutical companies to access specialized facilities, technical expertise, and scalable production infrastructure without building all capabilities internally. Increasing biologics complexity and the need for flexible manufacturing capacity continue to support strong demand for contract manufacturing services.
Contract research is the fastest-growing service segment as biopharmaceutical developers increasingly outsource research activities to access specialized scientific expertise and advanced capabilities. External research organizations can support activities ranging from discovery and preclinical development to analytical and clinical research, helping sponsors manage increasingly complex development programs. Rising pipeline activity and the need to accelerate innovation while controlling internal resource requirements are supporting greater adoption of contract research services.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Source | Mammalian, Non-mammalian | Mammalian | Non-mammalian |
| Service Type | Contract Manufacturing, Contract Research | Contract Manufacturing | Contract Research |
| Product | Biologics, Biosimilars | Biologics | Biosimilars |
Competitive Landscape and Market Positioning
Major players in the biopharmaceutical CMO and CRO market:
1. Lonza Group AG (Switzerland)
2. Thermo Fisher Scientific Inc. (United States)
3. WuXi Biologics (China)
4. Charles River Laboratories International Inc. (United States)
5. ICON plc (Ireland)
6. Parexel International Corporation (United States)
7. FUJIFILM Diosynth Biotechnologies U.S.A. Inc. (United States)
8. Boehringer Ingelheim International GmbH (Germany)
9. Rentschler Biopharma SE (Germany)
10. Samsung Biologics Co. Ltd. (South Korea)
The biopharmaceutical CMO and CRO market is evolving through increasing outsourcing of development and manufacturing services. In this market, integration of advanced technologies is improving efficiency and scalability. Collaborative service models are strengthening global research and production capabilities.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Lonza Group AG (Switzerland) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| WuXi Biologics (China) | |||||||
| Charles River Laboratories International Inc. (United States) | |||||||
| ICON plc (Ireland) | |||||||
| Parexel International Corporation (United States) | |||||||
| FUJIFILM Diosynth Biotechnologies U.S.A. Inc. (United States) | |||||||
| Boehringer Ingelheim International GmbH (Germany) | |||||||
| Rentschler Biopharma SE (Germany) | |||||||
| Samsung Biologics Co. Ltd. (South Korea). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Avance Clinical | 2026 | Avance Clinical acquired oncology-specialist CRO LumaBridge, expanding its clinical research footprint in the United States. The acquisition strengthens its therapeutic specialization in oncology trials and enhances its CRO service capabilities, supporting broader clinical development support for biopharmaceutical clients. |
| VivaMed BioPharma | Feb-26 | VivaMed BioPharma formed a strategic partnership with Syngene International to advance AI-driven drug repurposing programs. The collaboration integrates computational approaches with biopharmaceutical development workflows, supporting expanded innovation in early-stage drug discovery and strengthening contract research and development capabilities. |
| CHA Biotech | Jan-26 | CHA Biotech’s Matica BioLabs signed a contract manufacturing agreement with Ingenium Therapeutics focused on NK-cell–based regenerative therapies. The agreement expands CHA Biotech’s CMO activity in advanced cell therapy manufacturing and supports production scale-up for next-generation immunotherapy applications. |
| Samsung Biologics | Oct-23 | Samsung Biologics entered a strategic collaboration with Kurma Partners to support development and manufacturing of biologics for Kurma’s portfolio companies. The partnership strengthens Samsung Biologics’ European engagement and reinforces its role in contract manufacturing services for emerging biopharmaceutical developers across multiple therapeutic areas. |
| Lonza | Jun-23 | Lonza acquired Synaffix B.V., a biotechnology company specializing in antibody-drug conjugate (ADC) technology platforms. The acquisition enhances Lonza’s biopharmaceutical CMO capabilities by integrating Synaffix’s bioconjugation technologies and R&D expertise, strengthening its position in advanced biologics manufacturing and expanding its high-value therapeutic development services. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Biopharmaceutical CMO and CRO Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Therapeutic Area | Oncology, Immunology & Autoimmune Diseases, Infectious Diseases, Neurology & CNS Disorders, Other Therapeutic Areas |
| Development Stage | Preclinical & Discovery, Clinical Phase I, Clinical Phase II, Clinical Phase III, Commercial & Post-Approval |
| Client Type | Large Pharmaceutical Companies, Biotechnology Companies, Specialty & Emerging Biopharmaceutical Companies |
Biopharmaceutical CMO and CRO Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Outsourcing Decision Framework Analysis |
|
| Biologics Manufacturing Capacity Assessment |
|
| Emerging Modality Service Opportunities |
|
Need a different cut of the data?
Request Custom ResearchHow big is the biopharmaceutical CMO and CRO market?
How is the biopharmaceutical CMO and CRO industry expected to grow over the next 10 years?
How is biologics outsourcing reshaping capacity utilization in the biopharmaceutical CMO and CRO market?
Why is rising biologics pipeline complexity increasing reliance on specialized service providers in the biopharmaceutical CMO and CRO market?
Why is contract manufacturing the largest service type in the biopharmaceutical CMO and CRO market?
Why is non-mammalian the fastest-growing source segment in the biopharmaceutical CMO and CRO market?
Why does North America lead the biopharmaceutical CMO and CRO market?
What is driving growth in Asia Pacific biopharmaceutical CMO and CRO market?
Who are the major participants shaping the biopharmaceutical CMO and CRO landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization